

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/352367284>

Punicalagin and zinc (II) ions inhibit the activity of SARS-CoV-2 3CL-protease in vitro

Article in *European Review for Medical and Pharmacological Sciences* · May 2021

CITATIONS

4

READS

80

3 authors:



Mohamed Jamal Saadh

Middle East University-Amman-Jordan

66 PUBLICATIONS 113 CITATIONS

SEE PROFILE



Amany M. Alboghdadly

Ibn Sina National College for Medical Studies

17 PUBLICATIONS 45 CITATIONS

SEE PROFILE



Abeer Kharshid

Universiti Sains Malaysia

13 PUBLICATIONS 54 CITATIONS

SEE PROFILE

Some of the authors of this publication are also working on these related projects:



Cardiovascular Surgery [View project](#)



Vaccine [View project](#)

Punicalagin and zinc (II) ions inhibit the activity of SARS-CoV-2 3CL-protease *in vitro*

M.J. SAADH¹, A.M. ALMAAYTAH^{1,2}, M. ALARAJ¹, M.F. DABABNEH¹, I. SA'ADEH³, S.M. ALDALAEN⁴, A.M. KHARSHID⁴, A. ALBOGHDADLY⁵, M. HAILAT⁶, A. KHALEEL⁷, K.D. AL-HAMAIDEH⁸, W. ABU DAYYIH⁷

¹Faculty of Pharmacy, Middle East University, Amman, Jordan

²Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan

³Department of Radiology, King Abdulaziz Medical City, National Guard Hospital, Riyadh, Saudi Arabia.

⁴Faculty of Pharmacy, Mutah University, Amman, Jordan

⁵Department of Pharmacy Practice, Pharmacy Program, Batterjee Medical College, Jeddah, Saudi Arabia

⁶Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan

⁷Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, Jordan

⁸Department of Basic Medical Sciences, Faculty of Medicine, Al-Balqa Applied University, Amman, Jordan

Abstract. – **OBJECTIVE:** Coronavirus 2019 (COVID-19) has now been declared as a worldwide pandemic. Currently, no drugs have been endorsed for its treatment; in this manner, a pressing need has been developed for any antiviral drugs that will treat COVID-19. Coronaviruses require the SARS-CoV-2 3CL-Protease (3CL-protease) for cleavage of its polyprotein to yield a single useful protein and assume a basic role in the disease progression. In this study, we demonstrated that punicalagin, the fundamental active element of pomegranate in addition to the combination of punicalagin with zinc (Zn) II, appear to show powerful inhibitory activity against SARS-CoV-2.

MATERIALS AND METHODS: The 3CL protease assay kit was used to quantify 3CL protease action. The tetrazolium dye, MTS, was used to evaluate cytotoxicity.

RESULTS: Punicalagin showed inhibitory action against the 3CL-protease in a dose-dependent manner, and IC₅₀ was found to be 6.192 µg/ml for punicalagin. Punicalagin (10 µg/mL) demonstrated a significant inhibitory activity toward 3CL-protease activity ($p < 0.001$), yet when punicalagin is combined with zinc sulfate monohydrate (punicalagin/Zn-II) extremely strong 3CL-protease activity ($p < 0.001$) was obtained. The action of 3CL-protease with punicalagin/Zn-II was decreased by approximately 4.4-fold in contrast to only punicalagin (10 µg/mL). Likewise, we did not notice any significant cytotoxicity caused by punicalagin, Zn-II, or punicalagin/Zn-II.

CONCLUSIONS: We suggest that these compounds could be used as potential antiviral drugs against COVID-19.

Key Words:

Punicalagin, Zinc II, SARS-CoV-2 3CL-Protease, SARS-CoV-2, COVID-19.

Introduction

Currently, Coronavirus 2019 (COVID-19) is the main pandemic of the century since more than 95,000,000 people have been infected with this disease and more than 2,032,750 deaths have been reported as of January 2020¹. However, vaccination remains the best preventive measure against COVID-19 infections. Considering all aspects, inoculation viability is diminished due to a high transformation rate of COVID-19 infections, thereby causing adjustments in immunization composition that make vaccine development difficult and time-consuming².

Cleavage of viral polyproteins by proteases is an important aspect of the existing pattern of coronavirus, and a few viral proteases that are encoded in the coronavirus RNA are needed for the development of the viral proteins³. The

SARS-CoV-2 3CL-Protease (3CL-protease) is the only cysteine protease found in coronaviruses. It separates the COVID-19 polyprotein at eleven moderated sites, and it is essential for replication of the virus⁴⁻⁶. Considering its significance, the 3CL-protease is a target for antivirals, and few antiviral candidates were identified using a 3CL-protease test⁷⁻⁹. The 3CL-protease is one of the best drug targets among different corona viruses and functions to prevent virus replication. Because no similar enzyme in humans exists, these drugs tend to be non-toxic *vivo*¹⁰. Currently, synthetic compounds focusing on the CL-protease have been identified for inhibiting the replication of coronaviruses *in vivo*¹⁰.

The most abundant polyphenol in pomegranate is punicalagin, which has been implicated as the bioactive constituent responsible for > 50% of the juice's potent antioxidant activity¹¹. Punicalagin (MW 1084.7) and its major degradation product, ellagic acid, are thought to be the major bioactive phytochemicals present in pomegranate peel extract¹². It has been shown that punicalagin targets and inactivates herpes simplex virus (HSV)-1 particles and can prevent binding, attachment, penetration, and cell-to-cell spread of protease inhibitors thus inhibiting viral glycoprotein interactions with cell surface glycosaminoglycans¹³. Punicalagin has also been reported to be effective in abrogating infection caused by human cytomegalovirus, hepatitis C virus, dengue virus, measles virus, and respiratory syncytial virus (HCMV, HCV, DENV, MV, and RSV, respectively), at micromolar (μM) concentrations and in a dose-dependent manner without significant cytotoxicity¹⁴; therefore, the impact of punicalagin was not examined as an expected virucide.

Zinc (Zn) has been shown to have direct antiviral properties (for example, against flu) and antiviral activity when Zn (II) is combined and co-administered with plants¹⁵. Zn can inhibit the protease activity and polymerase enzymatic processes in addition to physical processes, such as virus attachment, infection, and uncoating¹⁵. The use of a combination of drugs is necessary and effective for reducing the risk of drug-resistant mutations.

In the current study, we analyzed the potentiated antiviral activity of punicalagin, Zn (II), and punicalagin combined with Zn (II) particles using an assay in which the activity of 3CL-Protease was inhibited *in-vitro*.

Materials and Methods

Materials

Punicalagin (purity $\geq 95\%$) and Zn sulfate monohydrate were purchased from Sigma Aldrich (Saint Louis, MO, USA).

Assay Protocol Against the 3CL Protease

The measure of the punicalagin, Zn II, or a combination of punicalagin with the Zn II on the activity of the 3CL protease was assessed using an improved 3CL Protease Assay Kit (BPS Bioscience, #78042, San Diego, USA). The fluorescence was estimated using a Tecan microplate fluorimeter equipped for excitation and emission at 360 and 460 nm, respectively (Tecan Biotek, Winooski, VT) according to the manufacturer's instructions described in the kit^{16,17}.

Cytotoxicity

Test solutions were analyzed for cytotoxicity using the Cell Titer 96 Aqueous Kit (Promega, Southampton, UK). Cells were plated in a 96-well-plate with a known concentration of Vero cells in each well. Cells (2.5×10^3) for each well was used for each plate after Vero cells had reached 80% confluence in a T75 flask (Greiner Bio-One, Stonehouse, UK). The cells were then plated in Dulbecco's Modified Eagle's Medium (DMEM) and cultivated for 24 hours at 37°C under 5% CO₂.

The medium was removed by aspiration, and the cells were washed multiple times with phosphate-buffered saline (PBS) after which the PBS was quickly replaced with DMEM media containing the ideal concentrations of test materials. Cells were incubated for 6, 24, 48 and 72 h. Cell titers were used to identify cell viability and were added to each well. Plates were incubated for 1 h at 37 °C under 5% CO₂. Optical thickness was then measured at 492 nm with the blank value subtracted from each sample reading and the mean thickness for the control cells were assigned a value of 100%.

Statistical Analysis

Data analysis was performed with the Graph-Pad Prism package and SPSS software. Differences among the studied groups were determined based on one-way analysis of variance (ANOVA) followed by Tukey's multiple comparisons as post-hoc test. $p < 0.05$ was considered significant.

Results

Inhibitory Effect of Punicalagin on 3CL Protease Activity

The activity of the 3CL-protease was determined (Figure 1). Likewise, we inspected the impact that punicalagin had on the 3CL-protease activity by testing different concentrations of punicalagin (0, 1, 2, 5, 10, 20, and 40 $\mu\text{g/ml}$). We found that punicalagin inhibited 3CL-protease activity (Figure 1). The half maximal inhibitory concentration (IC_{50}) of punicalagin was 6.192 $\mu\text{g/ml}$ (Figure 2). These results show that punicalagin is an inhibitor of 3CL-protease. Increasing the concentration of punicalagin above 10 μM did not yield any further inhibition of the protease (Figure 2). Thus, in resulting tests, 10 μM punicalagin was used.

The Inhibitory Effect of Punicalagin When Combined with Different Levels of Zinc Sulfate Monohydrate (Punicalagin/Zn-II) on 3CL Protease Activity

The impact of 10 $\mu\text{g/ml}$ punicalagin containing different concentrations of Zn sulfate monohydrate (0, 0.2, 0.5, 3, 5, 30, and 100 mg/ml) on the activity of the 3CL-protease was evaluated. The outcomes indicated that Zn sulfate inhibited 3CL-protease activity (Figure 3). These outcomes demonstrate that punicalagin is a more powerful inhibitor of 3CL-protease action than Zn sulfate.

Increasing levels of Zn sulfate were associated with a decrease in the activity of 3CL protease.




Figure 1. Punicalagin inhibits 3CL-protease *in vitro* at different concentration. The 3CL-protease activity was analyzed in triplicate, and the mean and standard deviation are shown. * $p > 0.05$, ** $p < 0.01$, *** $p < 0.001$.




Figure 2. The half maximal inhibitory concentration (IC_{50}) of punicalagin.

The maximum reduction in activity was observed when a combination of punicalagin with 3 mg/ml Zn sulfate monohydrate (Figure 3) was used. Increasing the concentration of Zn sulfate monohydrate to $> 3 \text{ mg/mL}$ did not cause an increase in its inhibitory effects.

Both punicalagin and Zn sulfate inhibited the 3CL protease. We analyzed whether punicalagin and Zn sulfate monohydrate together may have had an added or a synergistic inhibitory impact on 3CL-protease activity. We incubated cells with punicalagin alone, Zn sulfate alone, and punicalagin/Zn sulfate combination and estimated the inhibitory impact on the 3CL-protease. Using the observed protease activity, we determined the coefficient of drug association (CDI) and determined a CDI for punicalagin (10 $\mu\text{g/mL}$)




Figure 3. Punicalagin (10 $\mu\text{g/ml}$) with different zinc (Zn) sulfate monohydrate concentration inhibits 3CL-protease *in vitro*. The 3CL-protease activity was performed in triplicate.

and Zn sulfate monohydrate (3 mg/mL) of 0.272, demonstrating that punicalagin and Zn sulfate had a synergistic effect on the protease's activity (Figure 4).

For punicalagin/Zn-II, a 24% (4.4-fold) decrease in protease activity was estimated when compared with punicalagin alone (10 µg/ml) as shown in Figure 5.

Cytotoxicity

The cytotoxicity of 10 µg/mL punicalagin, 3 mg/mL Zn sulfate monohydrate, and combination of 10 µg/mL punicalagin with 3 mg/mL Zn sulfate monohydrate were evaluated using the tetrazolium dye, MTS, proliferation assay. No significant differences ($p > 0.05$) between the applied formulations any time over the 72 h were observed, indicating these drugs did not affect cell viability (Figure 6).

Discussion

The need for a COVID-19 treatment is critical as COVID-19 is spreading quickly, and infections/deaths are constantly rising worldwide. The 3CL protease is a promising target for COVID-19 treatment. Recently, a peptidomimetic α -ketoamide compound was demonstrated to inhibit the 3CL-protease and decrease viral replication in cell culture¹⁰. Likewise, epigallocatechin-3-gal-




Figure 5. The percentage decrease activity and fold decrease activity assay for both Punicalagin, and Punicalagin/Zn-II against 3CL-protease activity.

late (EGCG) and theaflavin appear to be promising compounds for inhibiting the 3CL-protease *in-vitro*^{11,18}. Nonetheless, further stringent testing should be done place to determine the safety and viability of these chemicals.

In this investigation, we analyzed whether punicalagin and punicalagin/Zn-II, the significant active ingredient of pomegranates, have inhibitory activity against the 3CL-protease. We showed that both punicalagin and punicalagin/Zn-II inhibited 3CL-protease activity. We found that an IC_{50} of 6.192 µg/mL for punicalagin was the critical concentration for causing a decrease in 3CL protease activity ($p < 0.001$) at 10 µg/mL of punicalagin. The constituents of pomegranate peel extract, to be specific punicalagin and punicalin, have the promising potential for critical




Figure 4. The activity assay of Zn sulfate monohydrate, Punicalagin, and Punicalagin/Zn-II against 3CL-protease activity; * $p < 0.01$, ** $p < 0.001$.




Figure 6. Cytotoxicity Effect of (1) Punicalagin (10 µg/mL), (2) zinc sulphate monohydrate (3 mg/mL), (3) the combination of Punicalagin (60µM) + zinc sulphate monohydrate (3 mg/mL). No cytotoxic effects were observed for all of the compounds at the concentrations used in this study.

interactions with the chosen protein targets and are accordingly considered acceptable candidates for additional *in vitro* and *in vivo* assessments¹⁹. A similar study showed that both theaflavin and EGCG produced a dose-dependent inhibitory effect on the 3CL protease. The IC₅₀ values were 8.44 µg/ml and 7.58 µg/ml for theaflavin and EGCG, respectively¹⁹.

Moreover, ZnII had direct antiviral properties against infections since it can impede protease activity and polymerase enzymatic cycles²⁰. Zn particles have recently been demonstrated as strong inhibitors of different RNA infections²¹. We observed that Zn induced a significant decline in 3CL-protease activity ($p < 0.01$).

One of the main questions about these compounds is whether their mixture increments could lead to 3CL-protease inhibition. Using a combination of 10 µg/mL punicalagin and 3 mg/mL Zn sulfate monohydrate, we noticed a significant decrease in 3CL-protease activity ($p < 0.001$), while not causing recognizable cytotoxicity. Inhibition of replication induced by pyrithione and Zn²⁺ over a range from 2 to 10 µM was recently reported for a few picornaviruses, for example, rhinoviruses, foot-and-mouth infections, coxsackievirus, and mengovirus^{22,23}.

Targeting the SARS enzyme as a potential target for drug discovery was done because of the lack of homologues in human hosts. Inhibitors of this enzyme have the capability of reducing viral replication and transcription without causing cell toxicity. In coronaviruses, Zn particles seem to inhibit both the proteolytic handling of replicate polyproteins²⁴ and SARS-CoV RdRp activity²¹. Likewise, late computational investigations have confirmed that polyphenols, for example, punicalagin, are inhibitors of SARS-CoV-2¹⁹.

Conclusions

Summarily, the combination of punicalagin and Zn particles inhibit the SARS-CoV-2 3CL-protease *in vitro*. In this study, we demonstrated that punicalagin, the active ingredient of pomegranate, is a powerful inhibitor of the 3CL protease *in-vitro*. In this way, pomegranate would be important for analyzing the impact of its active compound on the spread of SARS-CoV-2 *in vivo*. Also, further preliminary clinical trials will be needed to evaluate the impact of pomegranate use on the spread of COVID-19.

Conflict of Interest

The Authors declare that they have no conflict of interests.

Acknowledgements

The author is grateful to the Middle East University (MEU), Amman, Jordan, for the financial support granted to cover the publication fee of this research article. Also, this work was supported by MEU, Jordan (No. 2019MEU003).

References

- 1) https://www.worldometers.info/coronavirus/?utm_campaign=homeAdvegas1?%22.
- 2) Gómez-Carballa A, Bello X, Pardo-Seco J, Martín-Torres F, Salas A. Mapping the genome variation of SARS-CoV-2 worldwide highlights the impact of COVID-19 super-spreaders. *Genome Res* 2020; 30: 1434-1448.
- 3) Herold J, Gorbalenya AE, Thiel V, Schelle B, Siddell SG. Proteolytic processing at the amino terminus of human coronavirus 229E gene 1-encoded polyproteins: identification of a papain-like protease and its substrate. *J Virol* 1998; 72: 910-918.
- 4) Hsu MF, Kuo CJ, Chang KT, Chang HC, Chou CC, Ko TP, Hui-Lin Shr HL, Chang GG, Wang AHJ, Liang PH. Mechanism of the maturation process of SARS-CoV 3CL protease. *J Biol Chem* 2005; 280: 31257-31266.
- 5) Kim Y, Mandadapu SR, Groutas WC, Chang KO. Potent inhibition of feline coronaviruses with peptidyl compounds targeting coronavirus 3C-like protease. *Antiviral Res* 2012; 97: 161-168.
- 6) Hegyi A, Ziebuhr J. Conservation of substrate specificities among coronavirus main proteases. *J Gen Virol* 2002; 83: 595-599.
- 7) Chen LR, Wang YC, Lin YW, Chou SY, Chen SF, Liu LT, Wu YT, Kuo CJ, Chen TSS, Juang SH. Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors. *Bioorg Med Chem Lett* 2005; 15: 3058-3062.
- 8) Hsu JT, Kuo CJ, Hsieh HP, Wang YC, Huang KK, Lin CPC, Huang PF, Chen X, Liang PH. Evaluation of metal conjugated compounds as inhibitors of 3CL protease of SARS-CoV. *FEBS Letters* 2004; 574: 116-120.
- 9) Yang S, Chen SJ, Hsu MF, Wu JD, Tseng CTK, Liu YF, Chen HC, Kuo CW, Wu CS, Chang LW, Chen WC, Liao SY, Chang TY, Hung HH, Shr HL, Liu CY, Huang YA, Chang LY, Jen-Chi Hsu JC, Peters CJ, Wang AHJ, Ming-Chu Hsu MC. Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor. *J Med Chem* 2006; 49: 4971-4980.
- 10) Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R. Crystal structure of SARS-CoV-2 main protease

- provides a basis for the design of improved alpha-ketoamide inhibitors. *Science* 2020; 368: 409-412.
- 11) Gil MI, Tomas-Barberan FA, Hess-Pierce B, Holcroft DM, Kader AA. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. *J Agric Food Chem* 2000; 48: 4581-4589.
 - 12) Seeram NP, Lee R, Hardy M, Heber D. Rapid large-scale purification of ellagitannins from pomegranate husk, a by-product of the commercial juice industry. *Sep Purif Technol* 2005; 41: 49-55.
 - 13) Lin LT, Chen TY, Chung CY, Noyce RS, Grindley TB, McCormick C, Lin TC, Wang GH, Lin CC, Richardson CD. Hydrolyzable tannins (chebulagic acid and punicalagin) target viral glycoprotein-glycosaminoglycan interactions to inhibit herpes simplex virus 1 entry and cell-to-cell spread. *J Virol* 2011; 85: 4386-4398.
 - 14) Lin LT, Chen TY, Lin SC, Chung CY, Lin TC, Wang GH, et al. Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry. *BMC Microbiol* 2013; 13: 187.
 - 15) Scott AR, Stephanie O, Chantelle A, Golo A. The role of Zinc in antiviral immunity. *Adv Nutr* 2019; 10: 696-710.
 - 16) Morse JS, Lalonde T, Xu S, Liu WR. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. *ChemBioChem* 2020; 21: 730-738.
 - 17) Ghahremanpour MM, Tirado-Rives J, Deshmukh M, Ippolito JA, Zhang CH, de Vaca IC, Liosi ME, Anderson KS, Jorgensen WL. Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV 2. *ACS Med Chem Lett* 2020; 11: 2526-2533.
 - 18) Jang M, Park YI, Cha YE, Park R, Namkoong S, Lee JI, Park J. Tea Polyphenols EGCG and Theaflavin Inhibit the Activity of SARS-CoV-2 3CL-Protease In Vitro. *Evid Based Complement Alternat Med* 2020; 5630838: 7.
 - 19) Suručić R, Tubić B, Stojiljković MP, Djuric DM, Travar M, Grabež M, Šavikin K, Škrbić R. Computational study of pomegranate peel extract polyphenols as potential inhibitors of SARS-CoV-2 virus internalization. *Mol Cell Biochem* 2021: 476: 1179-1193.
 - 20) Scott AR, Stephanie O, Chantelle A, Golo A. The role of Zinc in antiviral immunity. *Adv Nutr* 2019; 10: 696-710.
 - 21) te Velthuis AJ, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. *PLoS Pathog* 2010; 6: e1001176.
 - 22) Lanke K, Krenn BM, Melchers WJG, Seipelt J, van Kuppeveld FJM. PDTC inhibits picornavirus polyprotein processing and RNA replication by transporting zinc ions into cells. *J Gen Virol* 2007; 88: 1206-1217.
 - 23) Krenn BM, Gaudernak E, Holzer B, Lanke K, Van Kuppeveld FJM, Seipelt J. Antiviral Activity of the Zinc Ionophores Pyrithione and Hinokitiol against Picornavirus Infections. *J Virol* 2009; 83: 58-64.
 - 24) Denison MR, Zoltick PW, Hughes SA, Giangreco B, Olson AL, Perlman S, Leibowitz JL, Weiss SR. Intracellular processing of the N-terminal ORF 1a proteins of the coronavirus MHV-A59 requires multiple proteolytic events. *Virology* 1992; 189: 274-284.